Clinical Trials Logo

Clinical Trial Summary

Inflammatory breast carcinoma (IBC) is an extremely rare, aggressive form of breast cancer that disproportionately impacts young women. IBC often affects the skin of the breast, as well as the breast itself, making it appear inflamed. The purpose of this study is to collect data and information on IBC patients so that researchers can study factors associated with IBC. The data and information collected will be used to establish the IBC Registry, a private cancer registry.

Approximately 300 persons who are 18 years or older and who have been diagnosed with IBC will participate in this study. Participants will provide researchers with access to their medical and pathology records, slides, tissue, and x-rays. They also will consent to a 15-minute telephone interview concerning general information about themselves and the initial manifestation of IBC and to a 30-minute interview about their medical history.


Clinical Trial Description

Inflammatory breast carcinoma (IBC) is an extremely rare, aggressive form of breast carcinoma that disproportionately affects young women. Clinical features of IBC include warmth, redness, edema, skin dimpling and rapid enlargement; the hallmark pathologically is dermal lymphatic invasion. Minimal criteria necessary for a clinical diagnosis of IBC have been debated and relatively little is known about the epidemiology, pathogenesis and molecular characteristics of these very lethal tumors. This project, funded by a grant from the Department of Defense awarded to PHL, would develop a national registry of approximately 300 volunteers (aged 18 years or older) with IBC. Subjects will provide access to medical records, pathology records, slides, blocks and tissue (fixed and frozen) and x-rays and consent to an interview. Recruitment will be performed at collaborating institutions and through an IBC research foundation (Owen Johnson) that maintains a website and e-mail contact lists. The registry resources would be made available collaboratively to anyone in the breast cancer research community, based on merit as determined by a designated committee. Central aims of the study include determining whether clinically or pathologically defined IBC differs in clinical behavior or biologically, identifying markers in IBC that may provide useful information about the aggressive potential of breast cancers generally, and evaluation of tissue for mouse mammary tumor virus (MMTV) related sequences. The purpose of this IRB submission is to review the role of MES as a collaborating pathologist on this study. Enrollment is closed as of this time. ;


Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT00340158
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date June 2003

See also
  Status Clinical Trial Phase
Completed NCT00344071 - Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia N/A
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Active, not recruiting NCT02221999 - Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Phase 2/Phase 3
Completed NCT02324088 - Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Phase 3
Completed NCT00003199 - Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Phase 2
Terminated NCT00016276 - Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Phase 3
Recruiting NCT01880385 - Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer Phase 1
Not yet recruiting NCT06131632 - Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy N/A
Completed NCT00513695 - Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer Phase 2
Recruiting NCT04636710 - Refining Local-Regional Therapy for IBC N/A
Active, not recruiting NCT05415215 - A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer Phase 3
Recruiting NCT04030507 - Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer N/A
Recruiting NCT03515798 - Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer Phase 2
Completed NCT01583426 - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Phase 3
Recruiting NCT02879513 - Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Phase 3
Completed NCT02199418 - Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Phase 2
Active, not recruiting NCT02623972 - A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Phase 2
Recruiting NCT00891280 - Dose-escalation Study of Oral CX-4945 Phase 1
Completed NCT00049114 - Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Phase 2
Active, not recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1